Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma
Abstract
Gastro-oesophageal cancers (GEC) are resistant to therapy and lead to poor prognosis. The cancer stem cells (CSCs) and antiapoptotic pathways often confer therapy resistance. We sought to elucidate the antitumour action of a BCL-2 inhibitor, AT101 in GEC in vitro, in vivo and in a clinical trial.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 24, 2021
- Source ID
- 10.1136/gutjnl-2020-321175
Entities
People
- Ailing W. Scott
- Arlene Correa
- Bin Liu
- Boyi Gan
- Brian Weston
- Cordelia Y Li
- Guang Lei
- Jaffer Ajani
- Jeannelyn Santiano Estrella
- Jeffrey H. Lee
- Jiankang Jin
- Lang Ma
- Lianchun Xiao
- Longfei Huo
- Manoop Bhutani
- Melissa Pool Pizzi
- Namita Shanbhag
- Qiongrong Chen
- Randy L Johnson
- Shaozhong Wei
- Shumei Song
- Wayne L. Hofstetter
- Ying Wang
- Yuan Li
Organizations
- Center for Scientific Review
- United States Department of Defense